



Supplemental Figure 1: Immunohistochemical analysis for VEGFR1 expression in mice ovaries of different groups one month after treatment; Ovarian sections with no primary antibody were served as negative controls. (A): control group; (B): Bu/Cy administrated group; (C): Bu/Cy+hAECs(24h) group; (D): Bu/Cy+hAECs-CM(24h) group; (E): Bu/Cy+hAECs(7d) group; (F): Bu/Cy+hAECs-CM(7d) group; (G): negative control. Scale bar: 100 μ m.



Supplemental Figure2: Immunohistochemical analysis for VEGFR2 expression in mice ovaries of different groups one month after treatment; Ovarian sections with no primary antibody were served as negative controls. (A): control group; (B): Bu/Cy-treated group; (C): Bu/Cy+hAECs(24h) group; (D): Bu/Cy+hAECs-CM(24h) group; (E): Bu/Cy+hAECs(7d) group; (F): Bu/Cy+hAECs-CM(7d) group; (G): negative control. Scale bar: 100 μ m.



Supplemental Figure 3: Immunohistochemical analysis for VEGFA expression in mice ovaries of different groups one month after treatment; Ovarian sections with no primary antibody were served as negative controls. (A): control group; (B): Bu/Cy-treated group; (C): Bu/Cy+hAECs(24h) group; (D): Bu/Cy+hAECs-CM(24h) group; (E): Bu/Cy+hAECs(7d) group; (F): Bu/Cy+hAECs-CM(7d) group; (G): negative control. Scale bar: 100 μ m.

